Literature DB >> 25994758

[Not Available].

M Warmuth-Metz1, B Bison2.   

Abstract

Mesh：

Year:  2015        PMID： 25994758     DOI： 10.1007/s00062-015-0406-y

Source DB:  PubMed          Journal:  Clin Neuroradiol        ISSN： 1869-1439            Impact factor:   3.649


× No keyword cloud information.
  4 in total

1.  Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma.

Authors:  Roger J Packer; Amar Gajjar; Gilbert Vezina; Lucy Rorke-Adams; Peter C Burger; Patricia L Robertson; Lisa Bayer; Deborah LaFond; Bernadine R Donahue; MaryAnne H Marymont; Karin Muraszko; James Langston; Richard Sposto
Journal:  J Clin Oncol       Date:  2006-09-01       Impact factor: 44.544

Review 2.  Neuroradiologic review in pediatric brain tumor studies.

Authors:  Monika Warmuth-Metz; Brigitte Bison; Susanne Leykamm
Journal:  Klin Neuroradiol       Date:  2009-11-21

3.  Long-term outcome and clinical prognostic factors in children with medulloblastoma treated in the prospective randomised multicentre trial HIT'91.

Authors:  Katja von Hoff; Bernward Hinkes; Nicolas U Gerber; Frank Deinlein; Uwe Mittler; Christian Urban; Martin Benesch; Monika Warmuth-Metz; Niels Soerensen; Isabella Zwiener; Heiko Goette; Paul G Schlegel; Torsten Pietsch; Rolf D Kortmann; Joachim Kuehl; Stefan Rutkowski
Journal:  Eur J Cancer       Date:  2009-02-26       Impact factor: 9.162

4.  Hyperfractionated versus conventional radiotherapy followed by chemotherapy in standard-risk medulloblastoma: results from the randomized multicenter HIT-SIOP PNET 4 trial.

Authors:  Birgitta Lannering; Stefan Rutkowski; Francois Doz; Barry Pizer; Göran Gustafsson; Aurora Navajas; Maura Massimino; Roel Reddingius; Martin Benesch; Christian Carrie; Roger Taylor; Lorenza Gandola; Thomas Björk-Eriksson; Jordi Giralt; Foppe Oldenburger; Torsten Pietsch; Dominique Figarella-Branger; Keith Robson; Marco Forni; Steven C Clifford; Monica Warmuth-Metz; Katja von Hoff; Andreas Faldum; Véronique Mosseri; Rolf Kortmann
Journal:  J Clin Oncol       Date:  2012-07-30       Impact factor: 44.544
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.